Mobile

A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-006698-25

A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl versus Placebo Concurrently with Pemetrexed (Alimta®) as Second Line Therapy in Patients with Advanced or Metastatic Non Small Cell Lung Cancer

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To compare pemetrexed plus enzastaurin when given in a twice daily dosing schedule versus pemetrexed plus placebo twice daily in terms of the progression-free survival time (PFS) of patients receiving second-line therapy for the treatment of locally advanced or metastatic NSCLC.

Critère d'inclusion

  • Advanced or Metastatic Non Small Cell Lung Cancer

Liens